Skip to main content
MJH Life Sciences
  • Login
  • Register
  • Login
  • Register
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences
MJH Life Sciences

SUBSCRIBE: Print / eNewsletter

AACR 2012

Inotuzumab Ozogamicin Achieves ‘Markedly Long’ Antitumor Response in Indolent B-Cell NHL

Inotuzumab ozogamicin has achieved a markedly long antitumor response in patients with refractory or relapsed indolent B-cell non-Hodgkin lymphoma (NHL) in an ongoing phase II study. Interim findings were reported by lead investigator Kenneth Luu, PhD, associate director of Pfizer global R&D.

  • READ >>
  • Add new comment

NIH Research Funding Faces ‘Unprecedented Threat’

Leaders of the American Association for Cancer Research (AACR) have expressed deep concern that the ability of cancer researchers to bring the promise of science to improve outcomes for cancer patients in the United States is in peril due to a decade of declining budgets at the National Institutes of Health (NIH).

  • READ >>
  • Add new comment

Hypofractionated Stereotactic Radiotherapy to Surgical Cavity After Resection for Brain Metastasis

Hypofractionated stereotactic radiotherapy (SRT) appears to be safe and effective in preventing recurrence at resection cavities following surgical resection of brain metastasis and may spare many patients from whole brain radiotherapy (WBRT) and its adverse effects.

  • READ >>
  • Add new comment

Development of a Novel Therapeutic Agent for Breast Cancer Based on a New Pathway Analysis of Triple-Negative Breast Cancer

Development of a novel method for drug discovery using active compounds as pharmacodynamic biomarkers in triple-negative breast cancer cell lines.

  • READ >>
  • Add new comment

'Striking' Results Seen in Phase II Trial of Selumetinib in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum

April 5, 2012
  • Michael Kaufman

Selumetinib, a small-molecule MEK inhibitor, controlled recurrent low-grade serous ovarian cancer in 81% of patients treated. Current first-line defense against this disease (surgery followed by cytotoxic chemotherapy) has met with limited success.

  • READ >>
  • Add new comment

Cytokine Signaling Through JAK2/STAT3 Pathway is a Viable Therapeutic Target in NSCLC

April 5, 2012
  • Michael Kaufman

Addition of a Janus kinase 2 (JAK2) inhibitor to therapies that target commonly altered oncogenes such as KRAS or EGFR could improve clinical outcomes for patients with non–small cell-lung cancer.

  • READ >>
  • Add new comment

Photoacoustic Tomography: Ultrasonically Breaking Through the Optical Diffusion Limit

April 5, 2012
  • Michael Kaufman

Photoacoustic tomography (PAT), a new imaging technique that relies on light and sound, provides in vivo multiscale nonionizing functional and molecular imaging without the radiation emitted by x-rays and CT scans, explained Lihong V. Wang, PhD, who led the team of developers at Washington University in St. Louis.

  • READ >>
  • Add new comment

Novel Approach of Phase I/II Trial Seeks Optimal Rather Than Maximum Tolerated Dose for Potent Epigenetic Drug Targeting Myelodysplastic Syndromes and Leukemia

April 4, 2012
  • Michael Kaufman

Preliminary findings of a phase I/II randomized clinical trial indicate that SGI-110, a novel DNA methylation inhibitor, is safe, well tolerated and efficacious in patients with acute myelogenous leukemia.

  • READ >>
  • Add new comment

Tremelimumab Shows Efficacy in Hepatocellular Carcinoma and Chronic Hepatitis C

April 4, 2012
  • Michael Kaufman

Treatment with tremelimumab stabilized patients with advanced hepatocellular carcinoma due to chronic hepatitis C infection for more than 12 months, according to data from a phase II clinical trial presented at the AACR annual meeting.

  • READ >>
  • Add new comment

Investigational Smac Mimetic TL32711 Targets Key Lymphoma Mechanism

April 3, 2012
  • Michael Kaufman

A combination of TL32711, an investigational second mitochondrial-derived activator of caspases (Smac), and tumor necrosis factor-related apoptosis inducing ligand at low concentrations produced marked apoptosis in germinal center lines, with minimal to no effect for each agent alone.

  • READ >>
  • Add new comment
Browse more articles

Resource Topics rightRail

  • Resource Topics
  • Partner Content
  • Breast Cancer
  • Acute Myeloid Leukemia
  • HER2-Positive Breast Cancer
  • Videos Breast Cancer
  • Follicular Lymphoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

ONCOLOGY Vol 33 No 11
Nov 21, 2019 Vol 33 No 11
Subscribe
Connect with Us
  • Column 1
    • Home
    • About Us
    • Contact Us
  • Column 2
    • Editorial Info
    • Editorial Board
  • Column 3
    • Advertising Info
    • Reprints
    • Advertising Terms
  • Column 4
    • Terms of Use
    • Privacy Policy
Modern Medicine Network
© UBM 2019, All rights reserved.
Reproduction in whole or in part is prohibited.

We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".